1. The effects of metformin with lifestyle therapy in polycystic ovary syndrome: a randomized double-blind study 
Gwinnett Ladson, M.D., William C. Dodson, M.D., Stephanie D. Sweet, M.D., Anthony E. Archibong, Ph.D., Allen R. Kunselman, M.A., Laurence M. Demers, Ph.D., Nancy I. Williams, Sc.D., Ponjola Coney, M.D., Richard S. Legro, M.D. 
Fertility and Sterility 
Volume 95, Issue 3, Pages e7 (March 2011)
DOI: /j.fertnstert
Copyright © 2011 American Society for Reproductive Medicine Terms and Conditions

2. Figure 1 Flow chart of study participants.
Fertility and Sterility  , e7DOI: ( /j.fertnstert )
Copyright © 2011 American Society for Reproductive Medicine Terms and Conditions

3. Figure 2
(A) Primary outcome: frequency of the number of ovulations by urinary pregnanediol-3 alpha-glucuronide per treatment arm. There was no difference between groups. This model adjusted for the covariates of prior metformin use, center, baseline age, and baseline body mass index in addition to use of the logarithm of the number of days on the trial as on offset to help account for subject dropout. Secondary outcomes: (B) change in testosterone levels at baseline, 3 months, and study completion at 6 months per treatment arm; (C) change in weight (kg) by month per treatment arm. ∗P<.05 for the change from baseline within the metformin group.
Fertility and Sterility  , e7DOI: ( /j.fertnstert )
Copyright © 2011 American Society for Reproductive Medicine Terms and Conditions

4. Glucose and insulin levels during 2-hour oral glucose tolerance test at baseline and study completion per treatment arm. There were no differences between groups at any timepoints.
Fertility and Sterility  , e7DOI: ( /j.fertnstert )
Copyright © 2011 American Society for Reproductive Medicine Terms and Conditions